Trevi Therapeutics (NASDAQ:TRVI - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $8.00 price target on the stock. Needham & Company LLC's target price suggests a potential upside of 203.03% from the company's current price.
Separately, Oppenheimer reissued an "outperform" rating and set a $9.00 price objective on shares of Trevi Therapeutics in a research report on Thursday, March 21st.
Check Out Our Latest Stock Report on Trevi Therapeutics
Trevi Therapeutics Price Performance
Shares of TRVI traded down $0.26 during trading hours on Wednesday, hitting $2.64. The stock had a trading volume of 116,736 shares, compared to its average volume of 258,560. Trevi Therapeutics has a 12 month low of $0.97 and a 12 month high of $4.00. The stock has a fifty day moving average price of $3.03 and a 200 day moving average price of $2.06. The firm has a market capitalization of $185.94 million, a PE ratio of -9.10 and a beta of 0.91.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its quarterly earnings results on Wednesday, March 20th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02. As a group, analysts anticipate that Trevi Therapeutics will post -0.39 EPS for the current fiscal year.
Institutional Investors Weigh In On Trevi Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Frazier Life Sciences Management L.P. grew its holdings in Trevi Therapeutics by 7.3% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company's stock valued at $9,891,000 after purchasing an additional 500,000 shares during the last quarter. Opaleye Management Inc. lifted its stake in shares of Trevi Therapeutics by 48.6% during the 4th quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company's stock worth $3,397,000 after acquiring an additional 829,100 shares during the last quarter. Silverarc Capital Management LLC boosted its holdings in Trevi Therapeutics by 4.7% during the 3rd quarter. Silverarc Capital Management LLC now owns 927,415 shares of the company's stock valued at $2,022,000 after acquiring an additional 41,491 shares during the period. SG Americas Securities LLC grew its position in Trevi Therapeutics by 401.4% in the 4th quarter. SG Americas Securities LLC now owns 98,253 shares of the company's stock valued at $132,000 after acquiring an additional 78,656 shares during the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new stake in Trevi Therapeutics in the first quarter worth $208,000. 95.76% of the stock is currently owned by hedge funds and other institutional investors.
Trevi Therapeutics Company Profile
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Read More
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
